Zevra Therapeutics to Participate at Upcoming Investor Conferences
2024年2月28日 - 9:30PM
Zevra Therapeutics, Inc. (NasdaqGS:
ZVRA) (Zevra or the Company), a rare disease
therapeutics company, today announced that Neil F. McFarlane,
President and Chief Executive Officer of Zevra, will present at
upcoming investor conferences in March 2024. Additionally,
management will be available for one-on-one meetings with
registered attendees at each of the conferences.
- Mr. McFarlane will present at the TD Cowen
44th Annual Health Care Conference in Boston, MA, on
Tuesday, March 5, 2024, at 2:10 p.m. ET.
- Mr. McFarlane will participate in a fireside chat at the 36th
Annual ROTH Conference in Dana Point, CA, on Monday, March 18,
2024, at 4 p.m. ET.
The live webcasts can be accessed through the
“Events & Presentations” section of Zevra’s website at
investors.zevra.com.
About Zevra Therapeutics:
Zevra Therapeutics is a rare disease company
combining science, data, and patient needs to create
transformational therapies for diseases with limited or no
treatment options. Our mission is to bring life-changing
therapeutics to people living with rare diseases. With unique,
data-driven development and commercialization strategies, the
Company is overcoming complex drug development challenges to make
new therapies available to the rare disease community.
Expanded access programs are made available by
Zevra Therapeutics and its affiliates and are subject to the
Company's Expanded Access Program (EAP) policy as published on its
website at www.zevra.com. Participation in these programs is
subject to the laws and regulations of each jurisdiction under
which each respective program is operated. Eligibility for
participation in any such program is at the treating physician's
discretion.
Cautionary Note Concerning
Forward-Looking Statements:
This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include all
statements that do not relate solely to historical or current
facts, and which can be identified by the use of words such as
"may," "will," "expect," "project," "estimate," "anticipate,"
"plan," "believe," "potential," "should," "continue," "could,"
"intend," "target," "predict," or the negative versions of those
words or other comparable words or expressions, although not all
forward-looking statements contain these identifying words or
expressions. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements
include without limitation statements regarding Zevra’s strategic
and product development objectives, including with respect to
becoming a leading rare disease company and addressing unmet
clinical needs, and Zevra’s plans, goals and expectations
concerning market position, future operations and other financial
and operating information. Forward-looking statements are based on
information currently available to Zevra and its current plans or
expectations, and are subject to several known and unknown
uncertainties, risks, and other important factors that may cause
actual results, performance, or achievements to be materially
different from any future results, performance, or achievements
expressed or implied by the forward-looking statements. These and
other important factors are described in detail in the “Risk
Factors” section of Zevra’s Annual Report on Form 10-K for the year
ended December 31, 2022, as updated in Zevra’s Quarterly Report on
Form 10-Q for the quarter ended September 30, 2023, and Zevra’s
other filings with the Securities and Exchange Commission. While
Zevra may elect to update such forward-looking statements at some
point in the future, it disclaims any obligation to do so, except
as required by law, even if subsequent events cause their
respective views to change. Although Zevra believes the
expectations reflected in such forward-looking statements are
reasonable, it cannot assure that such expectations will prove
correct. These forward-looking statements should not be relied upon
as representing Zevra’s views as of any date after the date of this
press release.
Zevra Contacts:
Nichol Ochsner +1 (732)
754-2545 nochsner@zevra.com
Russo Partners Contacts:
David Schull +1 (858)
717-2310 david.schull@russopartnersllc.com
Ignacio Guerrero-Ros, Ph.D. +1 (646)
942-5604 ignacio.guerrero-ros@russopartnersllc.com
Zevra Therapeutics (NASDAQ:ZVRA)
過去 株価チャート
から 4 2024 まで 5 2024
Zevra Therapeutics (NASDAQ:ZVRA)
過去 株価チャート
から 5 2023 まで 5 2024